The Aspr Barda Division Contracts Management & Acq, operating under the Office of the Assistant Secretary for Preparedness and Response within the Department of Health and Human Services, is dedicated to advancing biomedical preparedness and response capabilities for public health emergencies. Its c...
The Aspr Barda Division Contracts Management & Acq, operating under the Office of the Assistant Secretary for Preparedness and Response within the Department of Health and Human Services, is dedicated to advancing biomedical preparedness and response capabilities for public health emergencies. Its core mission centers on accelerating the development, validation, and scalable production of medical countermeasures against biological, chemical, radiological, and nuclear threats. Strategic priorities include the rapid innovation of diagnostic assays, vaccine platforms, and biological product manufacturing processes, with particular emphasis on pandemic readiness, radiation countermeasures, and advanced in vivo testing models. The agency prioritizes research and development in biotechnology and life sciences to enable next-generation medical solutions that can be rapidly deployed during crises.
Procurement patterns reveal a strong focus on R&D services supporting biomedical innovation, particularly in assay development, vaccine seed lot preservation, and nonclinical model standardization. The agency frequently issues presolicitations and sources-sought notices to engage industry early in the product lifecycle, leveraging flexible contracting mechanisms to support high-risk, high-reward scientific endeavors. Contracts often span preclinical validation, process development, and stability testing, reflecting an end-to-end approach to medical countermeasure readiness.
Industry preferences are heavily skewed toward research and development in biotechnology (NAICS 541714), with additional demand for pharmaceutical manufacturing, blood product sourcing, and specialized testing laboratories. While set-aside preferences are minimal, the agency actively seeks innovative small businesses and academic partners capable of delivering rapid, scalable solutions under urgent timelines. Vendor relationships are built around scientific rigor, regulatory alignment, and the ability to operate under accelerated development pathways.
Organized within the federal preparedness architecture, the agency operates nationally with no fixed physical footprint, coordinating contracts across academic, commercial, and government laboratories. It utilizes a mix of Other Transaction Authorities, SBIR/STTR mechanisms, and standard FAR-based contracts to enable agile acquisition of cutting-edge biomedical technologies.
